Cantor Fitzgerald downgraded Skye Bioscience (SKYE) to Neutral from Overweight with a price target of $2, down from $14.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience Reveals Phase 2a Study Results
- Why Is Skye Bioscience Stock Down 60% Today?
- Skye Bioscience says nimacimab did not meet primary endpoint in CBeyond study
- Buy Rating for Skye Bioscience: Nimacimab’s Potential in Obesity Treatment Market
- Skye Bioscience initiated with a Buy at H.C. Wainwright